Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms

Journal of Bone and Mineral Research

Volumn 22, Issue 11, 2007, Pages 1679-1689

  O'Sullivan, Susannah ^a   Naot, Dorit ^a   Callon, Karen ^a   Porteous, Fran ^a   Horne, Anne ^a   Wattie, Diana ^a   Watson, Maureen ^a   Cornish, Jill ^a   Browett, Peter ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Differentiation; Osteoblasts; Osteoclastogenesis; Osteoprotegerin; Platelet derived growth factor

Indexed keywords

ABELSON KINASE; CALCITRIOL; COLONY STIMULATING FACTOR 1; IMATINIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RNA; STEM CELL FACTOR; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION; STROMA CELL; ANIMAL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; RAT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 38449096127     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070719     Document Type: Article

References (36)

1. Savage DG, Antman KH 2002 Imatinib mesylate - a new oral targeted therapy. N Engl J Med 346:683-693.
2. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB 2005 Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105:3127-3132.
3. Taylor JR, Brownlow N, Domin J, Dibb NJ 2006 FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 25:147-151.
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M. Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, Investigators I 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004.
5. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011.
6. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG 2003 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214.
7. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J 2003 LRP: Role in vascular wall integrity and protection from atherosclerosis. Science 300:329-332.
8. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME 2004 Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 24:935-942.
9. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH 2006 Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116:2633-2642.
10. Gottardi M, Manzato E, Gherlinzoni F 2005 Imatinib and hyperlipidemia. N Engl J Med 353:2722-2723.
11. Veneri D, Franchini M, Bonora E 2005 Imatinib and regression of type 2 diabetes. N Engl J Med 352:1049-1050.
12. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M 2003 Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483-2487.
13. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916.
14. Li B, Boast S, de los Santos K, Schieren I, Quiroz M, Teitelbaum SL, Tondravi MM, Goff SP 2000 Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 24:304-308.
15. Lotinun S, Evans GL, Turner RT, Oursler MJ 2005 Deletion of membrane-bound steel factor results in osteopenia in mice. J Bone Miner Res 20:644-652.
16. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H 2006 Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24:274-282.
17. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC 2006 Imatinib as a potential antiresorptive therapy for bone disease. Blood 107:4334-4337.
18. El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S 2006 Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551:27-33.
19. Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S 2006 Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis 11:1909-1921.
20. Grey A, O'Sullivan S, Reid IR, Browett P 2006 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355:2494-2495.
21. Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Coy DH, Cooper GJ, Reid IR 1998 Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am J Physiol 274:E827-E833.
22. Groot CG, Danes JK, van der Meer JM, Herrmann-Erlee MP 1985 Osteocalcin antigenicity in cultured osteoblast-like cells after stimulation with 1,25-vitamin D3. Cell Biol Int Rep 9:528.
23. Herrmann-Erlee MPM, van der Meer JM 1986 The effect of PTH and PGE2 on growth and differentiation of primary fetal rat osteblast-like cells, on UMR 106 osteosarcoma cells, and on a SV40 transformed "osteoblast-like" cell line. International Conference IX on Calcium Regulating Hormones and Bone Metabolism, Montreal, Canada, 1986.
24. Grey A, Banovic T, Naot D, Hill B, Callon K, Reid I, Cornish J 2001 Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology 142:1098-1106.
25. Grey A, Chen Q, Xu X, Callon K, Cornish J 2003 Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 144:4886-4893.
26. Grey A, Chen Q, Callon K, Xu X, Reid IR, Cornish J 2002 The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Endocrinology 143:4755-4763.
27. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR 2001 Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29:162-168.
28. Naot D, Callon KE, Grey A, Cooper GJ, Reid IR, Cornish J 2001 A potential role for adrenomedullin as a local regulator of bone growth. Endocrinology 142:1849-1857.
29. Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D 2006 Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res 21:438-445.
30. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935-942.
31. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S. Scheu K, Wilson BA, Heller G, Sauter NP 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
33. Hock JM, Canalis E 1994 Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 134:1423-1428.
34. Canalis E, McCarthy TL, Centrella M 1989 Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol 140:530-537.
35. Centrella M, McCarthy TL, Canalis E 1989 Platelet-derived growth factor enhances deoxyribonucleic acid and collagen synthesis in osteoblast-enriched cultures from fetal rat parietal bone. Endocrinology 125:13-19.
36. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, Bornhauser M 2007 Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 40:355-366.